Blauvelt et al. [1] raise important questions about analysis of real-word drug performance data in response to our article “Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA” published in Dermatology and Therapy [2]. We appreciate this opportunity to address their questions and improve the understanding of methodologies and results of such analyses.
Anzeige
Determining persistence on a biologic with administrative claims data requires knowing when there is a gap in treatment, and the definition of a gap is complicated because the dosing regimens of different biologic products vary. Using a gap length proportional to the frequency of administration may favor biologics administered less frequently; using a fixed gap time may favor biologics administered more frequently. While our initial analysis was based on the former [2], analyses with fixed 90- and 60-day gaps to define discontinuation corroborate our findings; even when a fixed gap is used, median time to discontinuation and rates of discontinuation trend lower with guselkumab compared with other study biologics (Fig. 1A, B).
×
Blauvelt et al. noted that days of supply were imputed only for one study drug in our article [2]. No imputations were made for pharmacy claims of adalimumab, secukinumab, and ixekizumab because only 0.5% of adalimumab and 0.2% of both secukinumab and ixekizumab pharmacy claims in the maintenance phase had days of supply below 28 (the expected fill frequency for these biologics in maintenance phase). In all, 20.8% of guselkumab claims in the maintenance phase had 28–30 days of supply, while the labelled frequency is 56 days. Such discrepancy occurs for biologics with maintenance intervals greater than 4 weeks due to restrictions on the maximum of days of supply (typically, 30) imposed by some health plans [3]. Consistent with this hypothesis, the median time to next claim was 55 days among these claims; therefore, days of supply were imputed to 56.
Blauvelt et al. also noted limitations related to the unadjusted analysis in our article [2] as well as highlighted the need for supplementing persistence measures with adherence data. While we agree that a descriptive unadjusted analysis such as ours has limitations, it also affords an opportunity to consider multiple treatment options at the same time and evaluate a treatment landscape overall, which is not feasible with pairwise comparative studies. Nonetheless, to demonstrate that findings from our descriptive study remain robust in adjusted analyses, entropy balancing was used to adjust for differences in patient baseline characteristics, and guselkumab remained associated with about two times greater persistence compared with secukinumab and ixekizumab at 18 months after therapy initiation (Fig. 2A, B) [4, 5]. Approaches to calculating medication adherence such as the medication possession ratio (MPR) and the proportion of days covered (PDC) vary and must be tailored to the objectives of a specific study [6]. The Pharmacy Quality Alliance recommends using the PDC for chronic therapies [7], which is calculated as the number of days of supply over a fixed period (e.g., 18 months); using this approach, the mean PDC and the proportion of patients with PDC ≥ 80% trend higher for guselkumab compared with other study biologics (Table 1).
Table 1
Adherence to index biologic based on proportion of days covered1,2
Guselkumab cohort
Adalimumab cohort
Secukinumab cohort
Ixekizumab cohort
N = 3408
N = 8017
N = 6123
N = 3728
At 12 months of follow-up
Number of patients with available follow-up, n (%)
1887 (55.4)
5463 (68.1)
3930 (64.2)
2309 (61.9)
PDC, mean ± SD [median]
0.68 ± 0.26 [0.76]
0.62 ± 0.29 [0.69]
0.65 ± 0.28 [0.74]
0.63 ± 0.28 [0.73]
PDC ≥ 80%, n (%)
847 (44.9)
2199 (40.3)
1663 (42.3)
930 (40.3)
At 18 months of follow-up
Number of patients with available follow-up, n (%)
1368 (40.1)
4137 (51.6)
2818 (46.0)
1589 (42.6)
PDC, mean ± SD [median]
0.62 ± 0.28 [0.71]
0.54 ± 0.31 [0.54]
0.59 ± 0.29 [0.67]
0.58 ± 0.30 [0.65]
PDC ≥ 80%, n (%)
525 (38.4)
1321 (31.9)
982 (34.8)
544 (34.2)
At 24 months of follow-up
Number of patients with available follow-up, n (%)
843 (24.7)
2806 (35.0)
1775 (29.0)
904 (24.2)
PDC, mean ± SD [median]
0.59 ± 0.29 [0.67]
0.49 ± 0.31 [0.43]
0.55 ± 0.30 [0.58]
0.53 ± 0.31 [0.57]
PDC ≥ 80%, n (%)
288 (34.2)
729 (26.0)
539 (30.4)
263 (29.1)
1PDC was defined as the sum of non-overlapping days of supply of the index biologic divided by days in a fixed period (i.e., 12, 18, and 24 months) among patients followed for at least the same fixed period
2Evaluated during the follow-up period defined as the time between the index biologic initiation date and the earliest between the end of data or the end of continuous health plan eligibility
PDC proportion of days covered, SD standard deviation
×
Lastly, claims data indeed do not provide exact information on “disease control,” but lack of change in treatment may be a reasonable proxy. Defining remission with claims data also has limitations, but identifying patients off all psoriasis treatment (while remaining insured) may be a reasonable proxy for full remission. Being off systemic treatment may be a reasonable proxy for remission of moderate-to-severe psoriasis (allowing that topicals may be used for residual mild disease). These proxy definitions of remission are an exploratory approach; other reasons for remaining off biologic therapy include pregnancy, upcoming surgery, cancer diagnosis, or other patient factors [2]. While recognizing the limitations of this approach, the possibility of long-term treatment-free disease control we observed would likely be welcomed enthusiastically by patients and their physicians.
Anzeige
Declarations
Conflict of Interest
Timothy Fitzgerald is an employee of Janssen Scientific Affairs, LLC, and holds stock in Johnson & Johnson. Maryia Zhdanava, Dominic Pilon, Aditi Shah, and Patrick Lefebvre are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC. Steven R. Feldman received research, speaking and/or consulting support from Janssen Scientific Affairs, LLC and is the founder and majority owner of www.DrScore.com [drscore.com] and founder and part owner of Causa Research.
Ethical Approval
This letter is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.
Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.